Ani Pharmaceuticals (ANIP) Equity Average (2021 - 2023)

Ani Pharmaceuticals (ANIP) has 3 years of Equity Average data on file, last reported at $339.0 million in Q1 2023.

• For the quarter ending Q1 2023, Equity Average fell 3.8% year-over-year to $339.0 million; the trailing twelve-month figure through Mar 2023 stood at $339.0 million (down 3.8% YoY), and the FY2022 full-year result was $348.6 million, up 25.76% from the prior year.
• Equity Average was little changed at $339.0 million in Q1 2023, from $337.6 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $352.4 million in Q1 2022 to a low of $191.7 million in Q3 2021.
• A 3-year average of $310.6 million and a median of $337.6 million in 2022 frame the typical range for Equity Average.
• Across the five-year window, Equity Average soared 75.74% in 2022 and retreated 3.8% in 2023, its largest moves.
• Tracing ANIP's Equity Average over 3 years: stood at $275.1 million in 2021, then grew by 22.73% to $337.6 million in 2022, then rose by 0.42% to $339.0 million in 2023.
• Business Quant data shows ANIP's Equity Average at $339.0 million in Q1 2023, $337.6 million in Q4 2022, and $336.8 million in Q3 2022.